{"eventGroups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily. All patients receiving armodafinil, including patients that crossover, were evaluated for adverse events (AEs) and serious adverse events (SAEs).","id":"EG000","otherNumAffected":15,"otherNumAtRisk":50,"seriousNumAffected":2,"seriousNumAtRisk":50,"title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.\n\nAEs presented were those occurring during from Day 1 to Day 28 only","id":"EG001","otherNumAffected":2,"otherNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"title":"Placebo-First"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":50,"numEvents":2},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"G3/G4 Leukopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":50,"numEvents":3},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"G3/G4 Lymphopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":50,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Neutropenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 BUN (increased)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Creatinine (increased)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G4 Edema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Eosinophils (increased)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Hypokalemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Infection (ear)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Neuroma"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"G3/G4 Upper Respiratory Infection"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"Pneumonia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"Ptosis"}],"timeFrame":"8 weeks"}